Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalities

JCI Insight

Volumn 1, Issue 4, 2016, Pages

  Adam, Ryan J ^a,b   Hisert, Katherine B ^c   Dodd, Jonathan D ^d   Grogan, Brenda ^d   Launspach, Janice L ^b   Barnes, Janel K ^e   Gallagher, Charles G ^d   Sieren, Jered P ^b   Gross, Thomas J ^b   Fischer, Anthony J ^b   Cavanaugh, Joseph E ^e   Hoffman, Eric A ^a,b   Singh, Pradeep K ^c,f   Welsh, Michael J ^b,e   McKone, Edward F ^d   Stoltz, David A ^a,b  

^a University of Iowa   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991817857     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.86183     Document Type: Article

References (74)

1. Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. N Engl J Med. 2015; 372(4):351-362.
2. Fisher JT, Zhang Y, Engelhardt JF. Comparative biology of cystic fibrosis animal models. Methods Mol Biol. 2011; 742:311-334.
3. Rogan MP, et al. Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth. Proc Natl Acad Sci U S A. 2010; 107(47):20571-20575.
4. Meyerholz DK, et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. Am J Respir Crit Care Med. 2010; 182(10):1251-1261.
5. Abou Alaiwa MH, et al. Neonates with cystic fibrosis have a reduced nasal liquid pH; a small pilot study. J Cyst Fibros. 2014; 13(4):373-377.
6. Fischer AJ, et al. Tracheomalacia is associated with lower FEV1 and Pseudomonas acquisition in children with CF. Pediatr Pulmonol. 2014; 49(10):960-970.
7. Michoud MC, et al. Role of the cystic fibrosis transmembrane conductance channel in human airway smooth muscle. Am J Respir Cell Mol Biol. 2009; 40(2):217-222.
8. Regamey N, et al. Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2008; 177(8):837-843.
9. Hays SR, Ferrando RE, Carter R, Wong HH, Woodruff PG. Structural changes to airway smooth muscle in cystic fibrosis. Tho rax. 2005; 60(3):226-228.
10. Balfour-Lynn IM, Elborn JS. "CF asthma": what is it and what do we do about it?. Thorax. 2002; 57(8):742-748.
11. Sanchez I, Powell RE, Pasterkamp H. Wheezing and airflow obstruction during methacholine challenge in children with cystic fibrosis and in normal children. Am Rev Respir Dis. 1993; 147(3):705-709.
12. Hiatt P, Eigen H, Yu P, Tepper RS. Bronchodilator responsiveness in infants and young children with cystic fibrosis. Am Rev Respir Dis. 1988; 137(1):119-122.
13. Kent BD, Lane SJ, van Beek EJ, Dodd JD, Costello RW, Tiddens HA. Asthma and cystic fibrosis: a tangled web. Pediatr Pulmonol. 2014; 49(3):205-213.
14. Vandebrouck C, et al. Evidence that CFTR is expressed in rat tracheal smooth muscle cells and contributes to bronchodilation. Respir Res. 2006; 7:113.
15. Norez C, Jayle C, Becq F, Vandebrouck C. Bronchorelaxation of the human bronchi by CFTR activators. Pulm Pharmacol Ther. 2014; 27(1):38-43.
16. Cook DP, et al. Cystic Fibrosis Transmembrane Conductance Regulator in Sarcoplasmic Reticulum of Airway Smooth Muscle. Implications for Airway Contractility. Am J Respir Crit Care Med. 2016; 193(4):417-426.
17. Adam RJ, et al. Air trapping and airflow obstruction in newborn cystic fibrosis piglets. Am J Respir Crit Care Med. 2013; 188(12):1434-1441.
18. Accurso FJ, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010; 363(21):1991-2003.
19. Ramsey BW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365(18):1663-1672.
20. Yu H, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012; 11(3):237-245.
21. Van Goor F, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009; 106(44):18825-18830.
22. Davies JC, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013; 187(11):1219-1225.
23. McKone EF, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med. 2014; 2(11):902-910.
24. Rowe SM, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014; 190(2):175-184.
25. Sawicki GS, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015; 192(7):836-842.
26. Ivacaftor (Kalydeco) [prescribing information]. Cambridge, Massachusetts, USA: Vertex Pharmaceuticals; 2012.
27. Hall GL, et al. Air trapping on chest CT is associated with worse ventilation distribution in infants with cystic fibrosis diagnosed following newborn screening. PLoS One. 2011; 6(8):e23932.
28. Sly PD, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med. 2009; 180(2):146-152.
29. Brody AS, Klein JS, Molina PL, Quan J, Bean JA, Wilmott RW. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr. 2004; 145(1):32-38.
30. Sly PD, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013; 368(21):1963-1970.
31. Bonnel AS, et al. Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease. Pediatr Pulmonol. 2004; 38(5):396-405.
32. Gerthoffer WT. Regulation of the contractile element of airway smooth muscle. Am J Physiol. 1991; 261(2 pt 1):L15-28.
33. Olsen CR, Stevens AE, McIlroy MB. Rigidity of tracheae and bronchi during muscular constriction. J Appl Physiol. 1967; 23(1):27-34.
34. Jensen A, Atileh H, Suki B, Ingenito EP, Lutchen KR. Selected contribution: airway caliber in healthy and asthmatic subjects: effects of bronchial challenge and deep inspirations. J Appl Physiol (1985). 2001; 91(1):506-515.
35. Brown RH, Wizeman W, Danek C, Mitzner W. Effect of bronchial thermoplasty on airway distensibility. Eur Respir J. 2005; 26(2):277-282.
36. West AR, Needi ET, Mitchell HW, McFawn PK, Noble PB. Airways dilate to simulated inspiratory but not expiratory manoeuvres. Eur Respir J. 2012; 40(2):455-461.
37. Ward C, et al. Reduced airway distensibility, fixed airflow limitation, and airway wall remodeling in asthma. Am J Respir Crit Care Med. 2001; 164(9):1718-1721.
38. McParland BE, Macklem PT, Pare PD. Airway wall remodeling: friend or foe?. J Appl Physiol (1985). 2003; 95(1):426-434.
39. Dobrin PB. Mechanical properties of arterises. Physiol Rev. 1978; 58(2):397-460.
40. Sutton-Tyrrell K, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in wellfunctioning older adults. Circulation. 2005; 111(25):3384-3390.
41. Kelly RP, Millasseau SC, Ritter JM, Chowienczyk PJ. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. Hypertension. 2001; 37(6):1429-1433.
42. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens. 2005; 18(1 pt 2):3S-10S.
43. Wallace HL, Southern KW, Connell MG, Wray S, Burdyga T. Abnormal tracheal smooth muscle function in the CF mouse. Physiol Rep. 2013; 1(6):e00138.
44. Wilke M, et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. J Cyst Fibros. 2011; 10(suppl 2):S152-S171.
45. Kelly VJ, Brown NJ, King GG, Thompson BR. The bronchodilator response of in vivo specific airway compliance in adults with asthma. Ann Biomed Eng. 2011; 39(3):1125-1135.
46. Matsuba K, Thurlbeck WM. A morphometric study of bronchial and bronchiolar walls in children. Am Rev Respir Dis. 1972; 105(6):908-913.
47. James A, Carroll N. Airway smooth muscle in health and disease; methods of measurement and relation to function. Eur Respir J. 2000; 15(4):782-789.
48. Hisert KB, et al. Ivacaftor-induced proteomic changes suggest monocyte defects may contribute to the pathogenesis of cystic fibrosis. Am J Respir Cell Mol Biol. 2016; 54(4):594-507.
49. Hahn HL, Watson A, Wilson AG, Pride NB. Influence of bronchomotor tone on airway dimensions and resistance in excised dog lungs. J Appl Physiol Respir Environ Exerc Physiol. 1980; 49(2):270-278.
50. Gunst SJ, Stropp JQ, Service J. Mechanical modulation of pressure-volume characteristics of contracted canine airways in vitro. J Appl Physiol (1985). 1990; 68(5):2223-2229.
51. Brown RH, Mitzner W. Effect of lung inflation and airway muscle tone on airway diameter in vivo. J Appl Physiol (1985). 1996; 80(5):1581-1588.
52. Brown RH, Mitzner W, Bulut Y, Wagner EM. Effect of lung inflation in vivo on airways with smooth muscle tone or edema. J Appl Physiol (1985). 1997; 82(2):491-499.
53. Brown RH, Wizeman W, Danek C, Mitzner W. In vivo evaluation of the effectiveness of bronchial thermoplasty with computed tomography. J Appl Physiol (1985). 2005; 98(5):1603-1606.
54. Brown NJ, Salome CM, Berend N, Thorpe CW, King GG. Airway distensibility in adults with asthma and healthy adults, measured by forced oscillation technique. Am J Respir Crit Care Med. 2007; 176(2):129-137.
55. Kermode JA, et al. The effect of airway remodelling on airway hyper-responsiveness in asthma. Respir Med. 2011; 105(12):1798-1804.
56. Pyrgos G, Scichilone N, Togias A, Brown RH. Bronchodilation response to deep inspirations in asthma is dependent on airway distensibility and air trapping. J Appl Physiol (1985). 2011; 110(2):472-479.
57. Kelly VJ, Brown NJ, Sands SA, Borg BM, King GG, Thompson BR. Effect of airway smooth muscle tone on airway distensibility measured by the forced oscillation technique in adults with asthma. J Appl Physiol (1985). 2012; 112(9):1494-1503.
58. Brown RH, Scichilone N, Mudge B, Diemer FB, Permutt S, Togias A. High-resolution computed tomographic evaluation of airway distensibility and the effects of lung inflation on airway caliber in healthy subjects and individuals with asthma. Am J Respir Crit Care Med. 2001; 163(4):994-1001.
59. Johns DP, Wilson J, Harding R, Walters EH. Airway distensibility in healthy and asthmatic subjects: effect of lung volume history. J Appl Physiol (1985). 2000; 88(4):1413-1420.
60. Brown RH, Mitzner W, Wagner E, Permutt S, Togias A. Airway distension with lung inflation measured by HRCT. Acad Radiol. 2003; 10(10):1097-1103.
61. Reznikov LR, et al. CFTR-deficient pigs display peripheral nervous system defects at birth. Proc Natl Acad Sci U S A. 2013; 110(8):3083-3088.
62. Flume PA, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012; 142(3):718-724.
63. Polenakovik HM, Sanville B. The use of ivacaftor in an adult with severe lung disease due to cystic fibrosis (ΔF508/G551D). J Cyst Fibros. 2013; 12(5):530-531.
64. Harrison MJ, Murphy DM, Plant BJ. Ivacaftor in a G551D homozygote with cystic fibrosis. N Engl J Med. 2013; 369(13):1280-1282.
65. Barry PJ, et al. Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease. Chest. 2014; 146(1):152-158.
66. Hoare S, et al. Ivacaftor imaging response in cystic fibrosis. Am J Respir Crit Care Med. 2014; 189(4):484.
67. Yamashiro T, et al. Collapsibility of lung volume by paired inspiratory and expiratory CT scans: correlations with lung function and mean lung density. Acad Radiol. 2010; 17(4):489-495.
68. Zaporozhan J, et al. Paired inspiratory/expiratory volumetric thin-slice CT scan for emphysema analysis: comparison of different quantitative evaluations and pulmonary function test. Chest. 2005; 128(5):3212-3220.
69. Couper D, et al. Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax. 2014; 69(5):491-494.
70. Newell JD Jr, Sieren J, Hoffman EA. Development of quantitative computed tomography lung protocols. J Thorac Imaging. 2013; 28(5):266-271.
71. Busacker A, et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest. 2009; 135(1):48-56.
72. Tschirren J, McLennan G, Palagyi K, Hoffman EA, Sonka M. Matching and anatomical labeling of human airway tree. IEEE Trans Med Imaging. 2005; 24(12):1540-1547.
73. Smith BM, et al. Comparison of spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax. 2014; 69(11):987-996.
74. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med. 1995; 152(3):1107-1136